OSR Holdings, Inc. (NASDAQ:OSRH) Short Interest Update

OSR Holdings, Inc. (NASDAQ:OSRH) was the target of a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 264,011 shares, a growth of 16.4% from the February 12th total of 226,774 shares. Based on an average daily volume of 297,676 shares, the short-interest ratio is currently 0.9 days. Currently, 2.6% of the company’s shares are sold short. Currently, 2.6% of the company’s shares are sold short. Based on an average daily volume of 297,676 shares, the short-interest ratio is currently 0.9 days.

Institutional Investors Weigh In On OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP bought a new position in OSR Holdings, Inc. (NASDAQ:OSRH) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR at the end of the most recent quarter. Hedge funds and other institutional investors own 55.30% of the company’s stock.

OSR Stock Performance

NASDAQ OSRH opened at $0.43 on Thursday. The stock has a market cap of $11.12 million, a price-to-earnings ratio of -0.39 and a beta of 1.54. The business has a 50 day simple moving average of $0.55 and a 200 day simple moving average of $0.60. OSR has a 52-week low of $0.38 and a 52-week high of $4.33.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.